Cerity Partners LLC Sells 7,267 Shares of Medpace Holdings, Inc. $MEDP

Cerity Partners LLC lessened its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 16.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 35,717 shares of the company’s stock after selling 7,267 shares during the period. Cerity Partners LLC owned approximately 0.13% of Medpace worth $11,210,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in MEDP. Federated Hermes Inc. boosted its stake in shares of Medpace by 44.9% in the 2nd quarter. Federated Hermes Inc. now owns 31,950 shares of the company’s stock worth $10,028,000 after buying an additional 9,893 shares during the last quarter. Jump Financial LLC bought a new position in Medpace in the second quarter valued at about $15,729,000. Cary Street Partners Investment Advisory LLC boosted its position in Medpace by 514.3% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 215 shares of the company’s stock worth $67,000 after purchasing an additional 180 shares during the last quarter. Amundi boosted its position in Medpace by 1,987.6% in the second quarter. Amundi now owns 14,112 shares of the company’s stock worth $4,601,000 after purchasing an additional 13,436 shares during the last quarter. Finally, Epoch Investment Partners Inc. grew its stake in shares of Medpace by 11.4% during the 2nd quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock valued at $139,740,000 after purchasing an additional 45,435 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Truist Financial set a $555.00 price objective on shares of Medpace in a research note on Monday, October 27th. Rothschild & Co Redburn downgraded shares of Medpace from a “buy” rating to a “neutral” rating and increased their price target for the stock from $342.00 to $474.00 in a research report on Wednesday, September 3rd. Rothschild Redb cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. Zacks Research raised shares of Medpace from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 27th. Finally, BMO Capital Markets began coverage on Medpace in a research note on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have given a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, Medpace has a consensus rating of “Hold” and an average price target of $487.18.

Insider Transactions at Medpace

In other Medpace news, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the transaction, the vice president directly owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, President Jesse J. Geiger sold 21,503 shares of Medpace stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the sale, the president owned 15,000 shares in the company, valued at approximately $8,934,900. The trade was a 58.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 387,925 shares of company stock valued at $233,386,647 over the last 90 days. Company insiders own 20.30% of the company’s stock.

Medpace Price Performance

MEDP opened at $560.75 on Thursday. The company has a 50 day simple moving average of $569.80 and a two-hundred day simple moving average of $459.09. The firm has a market cap of $15.80 billion, a P/E ratio of 39.21, a PEG ratio of 2.05 and a beta of 1.43. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $626.26.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The company had revenue of $659.90 million for the quarter, compared to analysts’ expectations of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. Medpace’s revenue for the quarter was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.